MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
3.980
+0.180
+4.74%
After Hours: 3.900 -0.08 -2.01% 19:57 12/05 EST
OPEN
3.820
PREV CLOSE
3.800
HIGH
4.080
LOW
3.808
VOLUME
505.90K
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
1.000
MARKET CAP
189.48M
P/E (TTM)
-1.4187
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SABS last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at SABS last week (1117-1121)?
Weekly Report · 11/24 09:54
SAB Biotherapeutics Reports Positive Q3 2025 Earnings
TipRanks · 11/18 03:59
SAB Biotherapeutics Price Target Maintained With a $12.00/Share by Chardan Capital
Dow Jones · 11/17 12:23
SAB Biotherapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 11/17 12:23
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
Benzinga · 11/17 12:13
Weekly Report: what happened at SABS last week (1110-1114)?
Weekly Report · 11/17 09:54
Promising Clinical Developments and Strategic Decisions Justify Buy Rating for SAB Biotherapeutics
TipRanks · 11/14 11:36
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.